full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for September, 2014

26
Sep

Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland’s BioMotiv, buying into the accelerator’s promise to transform academic discoveries into market-bound therapeutics. …read more Source: Takeda pours $25M into biotech dealmaker BioMotiv     

26
Sep

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections. …read more Source: Gilead nears EU approval for the next big thing in hep C     

25
Sep

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that’s the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential. …read more Source: Valeant talks […]

25
Sep

Jockeying with a slew of next-generation treatments, Novartis’ new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company’s hopes of snagging significant market share once it wins approval. …read more Source: Novartis’ blockbuster hopeful scores a win in psoriatic arthritis     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off